Abstract 4279
Background
Conventional chemotherapy agents such as doxorubicinare not curative and new therapies for metastatic sarcomas are urgently needed. Apatinib (YN968D1) as a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) has been widely used as monotherapy or combined treatments. We performed a retrospective study with stage IV sarcoma cohort to investigate the efficacy of Apatinib with or without chemotherapy.
Methods
The information of 74 sarcoma patients in stage IV treated in Tianjin Medical University Cancer Hospital was collected and approved by the Institutional Review Board. Of these patients, 15 patients underwent Apatinib + traditional chemotherapy (combined group), and 59 received Apatinib as monotherapy (control group).
Results
We recruited 74 patients in this trial from Sep. 2015 to Apr. 2019. In the combined group, 6 of 15 patients (40.0%) recorded as partial response (PR), 7 of 15 patients (46.7%) recorded as stable disease (SD) and 2 patients (13.3%) was progressive disease (PD). The control group showed that 9 patients experienced PR (15.3%), 25 patients (42.4%) was SD and 25 patients (42.4%) was PD. The ORR (40.00% versus 15.25%, P = 0.034) and the DCR (86.67% versus 57.63%, P = 0.037) in the combined group showed significant higher than that of the control group. The median PFS of the combined group and control groups was 7.6 months and 7.9 months (P = 0.410). The median OS of the combined group and control group was 12.9 months and 17.3 months, respectively (P = 0.826). The mPFS and mOS shown no significant difference might due to the shorter follow-up time and small case number. Common AEs in combined group included hypertension (n = 7, 46.67%), hand-foot syndrome (n = 7, 46.67%), proteinuria (n = 8, 53.33%), anorexia (n = 4, 26.67%), fatigue (n = 4, 26.67%), transaminase increased (n = 4, 26.67%), diarrhea (n = 7, 46.67%), and anemia (n = 8, 53.33%), which all happened more frequently than in control group. No grade 4 AEs occurred, but 3 patients (20%) suffered from grade 3 AEs, which were mainly hypertension, hand-foot syndrome and proteinuria.
Conclusions
Chemotherapy combined with apatinib significantly increases the response rate and shows manageable adverse events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract